NASDAQ:TRDA Entrada Therapeutics (TRDA) Stock Price, News & Analysis $4.99 +0.17 (+3.53%) Closing price 04:00 PM EasternExtended Trading$4.99 0.00 (-0.10%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Entrada Therapeutics Stock (NASDAQ:TRDA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Entrada Therapeutics alerts:Sign Up Key Stats Today's Range$4.79▼$5.2750-Day Range$4.37▼$7.7852-Week Range$4.11▼$16.45Volume403,064 shsAverage Volume330,591 shsMarket Capitalization$194.31 millionP/E RatioN/ADividend YieldN/APrice Target$17.75Consensus RatingHold Company Overview Entrada Therapeutics, Inc. is a biotechnology company focused on developing medicines that address diseases caused by genetic abnormalities. The company’s research centers on its proprietary Endosomal Escape Vehicle (EEV) platform, which is designed to transport therapeutic cargo into cells and release it from endosomes, potentially enabling treatment of targets that have been difficult to reach with conventional drug-delivery approaches. Entrada is developing EEV-based therapeutics using modalities such as oligonucleotides, including compounds intended to modify RNA or influence gene expression. Its pipeline has included programs for rare genetic and neuromuscular disorders, including Duchenne muscular dystrophy and myotonic dystrophy type 1. The company’s Duchenne programs are designed to promote exon skipping for specific genetic mutations, with the goal of helping cells produce a functional form of dystrophin. Founded in 2016 and headquartered in Boston, Massachusetts, Entrada conducts research and clinical development aimed at serving patients with serious diseases in the United States and other global markets. As a clinical-stage biotechnology company, its products remain in development and are subject to the outcomes of clinical trials, regulatory review and other development requirements.AI Generated. May Contain Errors. Read More Entrada Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreTRDA MarketRank™: 3.00571884559 of 5 starsEntrada Therapeutics scored higher than 60% of companies evaluated by MarketBeat, and ranked 354th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingEntrada Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialEntrada Therapeutics has a consensus price target of $17.75, representing about 255.7% upside from its current price of $4.99.Amount of Analyst CoverageEntrada Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Entrada Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Entrada Therapeutics are expected to grow in the coming year, from ($4.03) to ($3.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Entrada Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Entrada Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEntrada Therapeutics has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Entrada Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.48% of the float of Entrada Therapeutics has been sold short.Short Interest Ratio / Days to CoverEntrada Therapeutics has a short interest ratio ("days to cover") of 9.86.Change versus previous monthShort interest in Entrada Therapeutics has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEntrada Therapeutics does not currently pay a dividend.Dividend GrowthEntrada Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.47 News SentimentEntrada Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Entrada Therapeutics this week, compared to 3 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Entrada Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,725,291.00 in company stock.Percentage Held by Insiders9.49% of the stock of Entrada Therapeutics is held by insiders.Percentage Held by Institutions86.39% of the stock of Entrada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Entrada Therapeutics' insider trading history. Receive TRDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRDA Stock News HeadlinesEntrada Therapeutics Advances Duchenne Study To Highest Planned Dose LevelOctober 14, 2026 | rttnews.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 StudyOctober 14, 2026 | markets.businessinsider.comDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarter he swaps in a brand-new list, and once the new edition launches, this one disappears. Investors who want a current snapshot of his picks should grab a copy now and save it before the switch happens.October 20 at 1:00 AM | Profits Run (Ad)Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45October 14, 2026 | globenewswire.comIndependent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyOctober 14, 2026 | globenewswire.comEntrada Therapeutics: Weak Dystrophin Data May Be Creating A Buying OpportunityOctober 10, 2026 | seekingalpha.comEntrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | finanznachrichten.deEntrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant ProgramSeptember 10, 2026 | globenewswire.comSee More Headlines TRDA Stock Analysis - Frequently Asked Questions How have TRDA shares performed this year? Entrada Therapeutics' stock was trading at $10.28 at the start of the year. Since then, TRDA stock has decreased by 51.5% and is now trading at $4.99. How were Entrada Therapeutics' earnings last quarter? Entrada Therapeutics, Inc. (NASDAQ:TRDA) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.97) by $0.04. The firm earned $0.90 million during the quarter, compared to analysts' expectations of $2.32 million. Entrada Therapeutics had a negative trailing twelve-month return on equity of 57.61% and a negative net margin of 3,537.73%. When did Entrada Therapeutics IPO? Entrada Therapeutics (TRDA) raised $182 million in an initial public offering on Thursday, October 28th 2021. The company issued 9,075,000 shares at a price of $19.00-$21.00 per share. How do I buy shares of Entrada Therapeutics? Shares of TRDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/05/2026Today10/20/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 TRDA's financial health is in the Red zone, according to TradeSmith. TRDA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TRDA CIK1689375 Webwww.entradatx.com Phone857-520-9158FaxN/AEmployees152Year Founded2016Price Target and Rating Average Price Target for Entrada Therapeutics$17.75 High Price Target$23.00 Low Price Target$11.00 Potential Upside/Downside+255.7%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($3.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$143.75 million Net Margins-3,537.73% Pretax Margin-3,520.25% Return on Equity-57.61% Return on Assets-46.54% Debt Debt-to-Equity RatioN/A Current Ratio10.89 Quick Ratio10.89 Sales & Book Value Annual Sales$25.42 million Price / Sales7.64 Cash FlowN/A Price / Cash FlowN/A Book Value$8.01 per share Price / Book0.62Miscellaneous Outstanding Shares38,940,000Free Float35,242,000Market Cap$194.31 million OptionableOptionable Beta-0.24 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:TRDA) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
